Clonal heterogeneity in patients with cytogenetically normal acute myeloid leukemia with NPM1 mutations
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14740%2F13%3A00067503" target="_blank" >RIV/00216224:14740/13:00067503 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/65269705:_____/13:#0002209
Výsledek na webu
<a href="http://informahealthcare.com/doi/abs/10.3109/10428194.2012.734618" target="_blank" >http://informahealthcare.com/doi/abs/10.3109/10428194.2012.734618</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3109/10428194.2012.734618" target="_blank" >10.3109/10428194.2012.734618</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Clonal heterogeneity in patients with cytogenetically normal acute myeloid leukemia with NPM1 mutations
Popis výsledku v původním jazyce
The nucleophosmin 1 (NPM1) gene is one of the most commonly mutated genes in acute myeloid leukemia (AML), occurring in approximately 60% of adult cytogenetically normal AML (CN-AML). To date, these mutations have only been detected in cells of the myeloid lineage, whereas the potential clonal involvement of the lymphoid lineage is controversial. In our study, NPM1 mutations were analyzed using the highly sensitive real-time quantitative polymerase chain reaction (RQ-PCR) method on fluorescence-activated cell-sorted (FACS) purified different circulating mature cell populations in patients with NPM1-mutated CN-AML. As expected, NPM1 mutations were found in myeloid blood cells, including CD14(+) monocytes and CD66b(+) granulocytes. However, we were alsoable to detect NPM1 mutations in CD19(+) B cells and CD3(-)14(-)16(+)56(+) natural killer (NK) cells, albeit at lower levels. Surprisingly, mutations were also detected in CD3(+) T cells from all analyzed patients.
Název v anglickém jazyce
Clonal heterogeneity in patients with cytogenetically normal acute myeloid leukemia with NPM1 mutations
Popis výsledku anglicky
The nucleophosmin 1 (NPM1) gene is one of the most commonly mutated genes in acute myeloid leukemia (AML), occurring in approximately 60% of adult cytogenetically normal AML (CN-AML). To date, these mutations have only been detected in cells of the myeloid lineage, whereas the potential clonal involvement of the lymphoid lineage is controversial. In our study, NPM1 mutations were analyzed using the highly sensitive real-time quantitative polymerase chain reaction (RQ-PCR) method on fluorescence-activated cell-sorted (FACS) purified different circulating mature cell populations in patients with NPM1-mutated CN-AML. As expected, NPM1 mutations were found in myeloid blood cells, including CD14(+) monocytes and CD66b(+) granulocytes. However, we were alsoable to detect NPM1 mutations in CD19(+) B cells and CD3(-)14(-)16(+)56(+) natural killer (NK) cells, albeit at lower levels. Surprisingly, mutations were also detected in CD3(+) T cells from all analyzed patients.
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FD - Onkologie a hematologie
OECD FORD obor
—
Návaznosti výsledku
Projekt
—
Návaznosti
Z - Vyzkumny zamer (s odkazem do CEZ)
Ostatní
Rok uplatnění
2013
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Leukemia & Lymphoma
ISSN
1042-8194
e-ISSN
—
Svazek periodika
54
Číslo periodika v rámci svazku
5
Stát vydavatele periodika
GB - Spojené království Velké Británie a Severního Irska
Počet stran výsledku
5
Strana od-do
1056-1060
Kód UT WoS článku
000317661900026
EID výsledku v databázi Scopus
—